Genmab

Photo
22.05.2024 • News

Genmab Completes Acquisition of ProfoundBio

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) and ADC technologies for the treatment of cancers.

Photo
04.04.2024 • News

Genmab to Acquire ProfoundBio for $1.8 Billion

Danish drugmaker Genmab has agreed to buy privately-owned US biotechnology company ProfoundBio for $1.8 billion. ProfoundBio develops novel ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.